Study guide

18.5 Systemic Sclerosis & Scleroderma Renal Crisis

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

18.5 Systemic Sclerosis & Scleroderma Renal Crisis

Key Takeaways Explain This Topic AI

Anti-centromere antibody associates with limited cutaneous disease and pulmonary arterial hypertension; anti-Scl-70 (topoisomerase I) with diffuse disease and interstitial lung disease.

Scleroderma renal crisis is treated with an ACE inhibitor even in the presence of rising creatinine, and corticosteroids above 15 mg prednisolone daily increase the risk of precipitating it.

Anti-RNA polymerase III antibody predicts diffuse skin disease and the highest risk of scleroderma renal crisis.

Last updated: September 2026

5. Systemic Sclerosis (Scleroderma)

Systemic sclerosis (SSc) is a multisystem disorder characterized by widespread microvascular obliterative vasculopathy, immune dysregulation, and excessive extracellular matrix (chiefly type I and III collagen) accumulation in skin and internal organs.

Subtypes: Limited Cutaneous vs. Diffuse Cutaneous SSc

Systemic sclerosis is classified based on the anatomical distribution of cutaneous fibrosis: Systemic Sclerosis Classification

  • |
  • +-----------------------------------+-----------------------------------+
  • | |
  • 1. Limited Cutaneous SSc (lcSSc / CREST) 2. Diffuse Cutaneous SSc (dcSSc)
  • Skin: Distal to elbows/knees + face - Skin: Proximal limbs + trunk + face
  • Long history of Raynaud's (decades) - Rapid onset; early visceral failure
  • Anti-Centromere Antibodies (70-80%) - Anti-Scl-70 (Topoisomerase I) / Anti-RNA Pol III
  • Late Complication: Isolated Precapillary - Complications: Severe Interstitial Lung Disease,
  • Pulmonary Arterial Hypertension (PAH) Scleroderma Renal Crisis (Emergency!)
  • Limited Cutaneous Systemic Sclerosis (lcSSc / CREST Syndrome)

Skin Involvement: Restricted to areas distal to the elbows and distal to the knees , and the face (spares the trunk, upper arms, and thighs).

Raynaud's Phenomenon: Often precedes skin sclerosis by decades. Microvascular cold-induced vasospasm exhibits classic triphasic color changes: white (pallor / digital ischaemia) -> blue (cyanosis / deoxygenation) -> red (rubor / reactive hyperemia).

The CREST Acronym:

C — Calcinosis Cutis: Painful, hard subcutaneous deposits of calcium hydroxyapatite in fingers, hands, and pressure points; can ulcerate and extrude chalky white material.

R — Raynaud's Phenomenon: Severe, with risk of digital pitting scars and ischaemic gangrene.

E — Oesophageal Dysmotility: Smooth muscle atrophy and fibrosis of the lower two-thirds of the oesophagus, with incompetence of the lower oesophageal sphincter. Manifests as severe refractory gastro-oesophageal reflux disease (GERD), dysphagia, and aspiration. Gastric antral vascular ectasia ( GAVE / "watermelon stomach" ) causes chronic occult GI bleeding.

S — Sclerodactyly: Thickening and tightening of the skin of the fingers, leading to tapering of digits, loss of normal skin creases, and fixed flexion contractures.

T — Telangiectasia: Distinctive, flat, polygonal "mat-like" vascular dilatations over the face, lips, oral mucosa, and palms.

Diagnostic Serology: Anti-Centromere Antibodies (ACA) are present in 70–80% of patients (giving a discrete speckled nuclear pattern on IF); highly specific for limited SSc.

Major Lethal Complication: Isolated Pulmonary Arterial Hypertension (PAH / WHO Group 1) . Develops insidiously late in the disease course (often 10–20 years post-diagnosis) due to proliferative obliterative vasculopathy of pulmonary arterioles without parenchymal fibrosis. Screened annually with transthoracic echocardiography, serum NT-proBNP, and serial pulmonary function tests showing a disproportionate reduction in gas transfer (isolated low DLCO with preserved FVC) . Gold-standard diagnosis requires right heart catheterization (mean pulmonary artery pressure > 20 mmHg with pulmonary capillary wedge pressure <= 15 mmHg and pulmonary vascular resistance >= 2 Wood units). Treated with endothelin receptor antagonists (bosentan, ambrisentan), PDE-5 inhibitors (sildenafil), and prostacyclin analogues.

Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Skin Involvement: Rapidly progressive, extensive skin sclerosis involving the trunk, abdomen, upper arms, and thighs , in addition to distal limbs and face. Associated with intense early pruritus and cutaneous hyperpigmentation with sparing of perifollicular skin ( "salt-and-pepper" depigmentation ).

Early Visceral Organ Involvement:

Interstitial Lung Disease (ILD): Major cause of death in dcSSc. Histopathology shows non-specific interstitial pneumonia (NSIP) or UIP. Presents with progressive exertional dyspnoea and dry cough; chest auscultation reveals fine "Velcro" bibasilar crackles. High-resolution CT (HRCT) demonstrates ground-glass opacities, traction bronchiectasis, and lower-lobe fibrosis. Pulmonary function tests show a restrictive ventilatory defect (reduced FVC < 80% predicted) with reduced DLCO .

Cardiac Involvement: Patchy myocardial fibrosis predisposing to diastolic dysfunction, heart failure, and life-threatening ventricular arrhythmias.

Diagnostic Serology:

Anti-Scl-70 (Anti-Topoisomerase I): Present in 30–40% of dcSSc patients; strongly associated with rapidly progressive diffuse skin thickening and severe interstitial lung disease .

Anti-RNA Polymerase III: Present in 15–20% of dcSSc patients; strongly associated with rapidly progressive extensive skin thickening and a massively heightened risk of Scleroderma Renal Crisis .

6. Scleroderma Renal Crisis (SRC)

Scleroderma renal crisis is a life-threatening medical emergency occurring in 10–15% of patients with diffuse cutaneous systemic sclerosis (most commonly within the first 4 years of diagnosis).

Pathophysiology & Corticosteroid Trigger

Mechanism: Severe microvascular endothelial injury in renal arcuate and interlobular arteries leads to marked intimal proliferation, "onion-skin" hyperplastic arteriolosclerosis, and microthrombosis. The resulting severe cortical renal ischaemia triggers massive, unregulated hypersecretion of renin by the juxtaglomerular apparatus ( hyperreninaemic renal crisis ).

High-Risk Precipitant: High-dose systemic corticosteroids (prednisolone > 15 mg/day) are a well-recognized direct trigger for SRC. Corticosteroids must be strictly avoided or used at the lowest possible dose in patients with diffuse SSc.

Autoantibody Risk: Presence of anti-RNA polymerase III antibodies confers the highest risk.

Clinical Presentation

Abrupt Onset of Severe Hypertension: Accelerated/malignant hypertension (typically systolic BP > 180 mmHg, diastolic BP > 110 mmHg; however, up to 10% may present with normotensive SRC, which carries an even worse prognosis).

Rapidly Progressive Oliguric AKI: Sudden, precipitous decline in renal clearance.

Hypertensive Encephalopathy & Cardiac Decompensation: Headache, papilloedema, visual disturbances, seizures, flash pulmonary oedema.

Microangiopathic Haemolytic Anaemia (MAHA) & Thrombocytopenia: Mechanical fragmentation of red blood cells passing through narrowed, fibrin-occluded renal arterioles produces circulating schistocytes (helmet cells) on peripheral blood film, marked elevation of LDH, indirect hyperbilirubinaemia, undetectable haptoglobin, negative direct Coombs test, and secondary consumptive thrombocytopenia.

Urinalysis: Mild proteinuria (usually < 2 g/24h) with microscopic haematuria and granular casts; broad nephrotic-range proteinuria is distinctly unusual.

Emergency Management

TREATMENT OF CHOICE: Immediate emergency initiation of an ACE inhibitor , specifically oral captopril (short-acting, easily titrated, started at 6.25–12.5 mg every 8 hours and rapidly escalated to maximum doses of 50 mg three times daily).

CRITICAL CLINICAL PEARL: ACE inhibitors must be aggressively titrated to normalize blood pressure EVEN IF THE SERUM CREATININE RISES INITIALLY . The transient rise in creatinine reflects reduced efferent arteriolar tone in the setting of underlying renal ischemia; failing to control the systemic hypertension results in irreversible bilateral renal cortical necrosis. Renal recovery is slow, frequently taking 12–24 months; up to 50% of patients requiring temporary haemodialysis can successfully discontinue dialysis if ACE inhibitors are continued indefinitely.